VTRs

VTRS is the ticker symbol for Viatris Inc., a multinational pharmaceutical company headquartered in Canonsburg, Pennsylvania. The company was formed in 2020 through the merger of Mylan N.V. and Upjohn Co., Pfizer’s legacy branded medicines business. Viatris began trading on the NASDAQ under the symbol VTRS on November 16, 2020, creating a global platform focused on generic and branded medicines.

Viatris develops, manufactures, and distributes a broad range of medicines, including generic and branded prescription drugs, biosimilars, and over-the-counter products, along with active pharmaceutical ingredients in some markets. It operates with a global footprint, supplying governments, healthcare providers, wholesalers, and retailers. The company emphasizes affordable access to medicines and aims to meet demand for high-quality, lower-cost therapies in both developed and emerging markets.

The company maintains manufacturing facilities and supply chains across multiple regions, with a global commercial organization that markets products in numerous countries. The portfolio reflects the blend of Mylan’s strength in generics and Upjohn’s branded portfolio, spanning therapeutic areas such as cardiovascular, infectious diseases, central nervous system, oncology, respiratory, and women’s health. Viatris also pursues collaborations and licensing arrangements to expand access and capabilities in biosimilars and complex generics.

As a publicly traded entity, Viatris emphasizes responsible pricing, regulatory compliance, and sustainability, while navigating competitive pressures in the evolving generics and biosimilars landscape. The company aims to optimize its cost structure and capital deployment to support ongoing operations, patient access, and long-term value for shareholders.